Cogent Biosciences, Inc. (COGT) SEC Filings & Earnings Calls

Dependence on single supplier for manufacturing; minimum purchase commitments may strain cash if demand falters.

“Agreement requires purchase of specified minimum percentages of requirements from Hovione.”

Regulatory approval uncertainty

“We may never succeed in obtaining regulatory approval for any of our product candidates.” · word for word

Significant operating losses and accumulated deficit

“As of June 30, 2026, we had an accumulated deficit of $1,382.2 million.” · word for word

Dependence on single product candidate

“Our most advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor.” · word for word

Share dilution from ATM and future financings

“To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing ownership interests will be diluted.” · word for word

Potential dilution from equity offering

“up to $400,000,000 of shares of Common Stock offered at market prices” · word for word

Regulatory approval risk for bezuclastinib

“Potential FDA approval dates in late 2026; no guarantee of approval.”

High cash burn rate

“R&D and G&A expenses increasing significantly; cash runway into late 2028 but dependent on no major delays.”

No approved products; history of losses

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Regulatory and clinical uncertainty

“We may never succeed in obtaining regulatory approval for any of our product candidates.” · word for word

Dependence on single lead asset bezuclastinib

“Our most advanced program is bezuclastinib, also known as CGT9486” · word for word

Regulatory risk: NDA approvals not guaranteed

“NDAs under FDA review; PDUFA date Dec 30, 2026 for NonAdvSM”

Regulatory and commercial execution risk

“Pending regulatory approval, we expect to launch bezuclastinib commercially in the United States in the second half of 2026.” · word for word

Dependence on single product candidate

“Our most advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is being studied in patients with Systemic Mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST).” · word for word

Significant net losses and negative cash flow

“Net Loss (in thousands) ... 2025 ... (328,937)”

Potential dilution from equity compensation

“Number of Securities to Be Issued Upon Exercise of Outstanding Options, Warrants and Rights ... 32,060,695” · word for word

Insider selling pressure

“On March 31, 2026, Fund II sold in a block trade a total of 7,000,000 shares of Common Stock at a price of $34.66 per share.” · word for word

Insider selling pressure

“On March 31, 2026, Fund II sold in a block trade a total of 7,000,000 shares of Common Stock at a price of $34.66 per share.” · word for word

Regulatory approval risk; NDA submissions may not be accepted or approved.

“NDA submissions subject to FDA review and approval.”

Single-source supplier dependency for API and drug product

“The API and drug product used in bezuclastinib are currently supplied to us from single-source suppliers.” · word for word

Clinical trial failure risk

“A failure of one or more clinical trials can occur at any stage of testing.” · word for word

Reimbursement uncertainty

“The pricing, coverage, and reimbursement of bezuclastinib and any other product candidates, if approved, must be adequate to support our commercial infrastructure.” · word for word

Elevated ALT/AST (≥Gr3 5.9%) led to discontinuations; all resolved.

“Discontinuations due to treatment-related AEs occurred in 5.9% of patients... all due to ALT/AST elevations and all patients fully resolved.” · word for word

Dilution from equity offering.

“Equity Underwriting Agreement” · word for word

Clinical-stage biotech with no approved products

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Significant operating losses and accumulated deficit

“As of September 30, 2025, we had an accumulated deficit of $1,085.9 million.” · word for word

Dependence on successful development and commercialization of bezuclastinib

“Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates.” · word for word

Need for substantial additional funding

“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word

Regulatory and clinical trial risks

“Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.” · word for word

Clinical trial failure risk: PEAK and APEX results pending; failure would impair pipeline value and cash runway.

“Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December.”